The final order on these reductions issued by the DEA establishes an aggregate production quota for the amount of opioids necessary to meet the estimated medical, scientific, research, industrial and export needs for 2017, while also maintaining reserve stocks.
Production quotas were reduced for oxycodone, hydrocodone, fentanyl, hydromorphone, morphine and other similar medications.
“Earlier this year the CDC issued guidelines to practitioners recommending a reduction in prescribing opioid medications for chronic pain,” the DEA said in a release. “For years, DEA and others have been educating practitioners, pharmacists, manufacturers and the public about the potential dangers of the misuse of opioid medications.”
More articles on supply chain:
Is Congress to blame for high drug prices?
Mylan pushes back release date of generic EpiPen
FDA approves St. Jude Medical’s spinal cord stimulation therapy
Becker’s 3rd Annual Fall Chief Pharmacy Officer Summit is the top tier event that the people leading the future of pharmacy convene. This 3-day event is built specifically for Chief Pharmacy Officers and senior pharmacy leaders. The sessions examine the workforce, financial and clinical priorities shaping pharmacy today. Becker’s is where candid discussions flourish and new ideas thrive. Becker's 3rd Annual Fall Chief Pharmacy Officer Summit
